| Japanese |
|---|
| Title | 拡張型心筋症にβ遮断薬治療を行い123I-MIBG心筋クリアランスと治療効果との関連が見られた2症例 |
|---|
| Subtitle | 症例報告 |
|---|
| Authors | 百瀬満*, 小林秀樹*, 斉藤克巳**, 堀江俊伸**, 牧正子*, 細田瑳一**, 日下部きよ子* |
|---|
| Authors(kana) | |
|---|
| Organization | *東京女子医科大学放射線科, **日本心臓血圧研究所循環器内科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 32 |
|---|
| Number | 3 |
|---|
| Page | 301-306 |
|---|
| Year/Month | 1995/3 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」拡張型心筋症と診断された2症例に対してβ遮断薬治療を行い, 治療前後で123I-MIBG心筋シンチグラフィを施行した. 症例1はβ遮断薬治療後, 約1か月の経過で自覚症状, および心機能の改善 (左室駆出率 : EF 19%から32%) を認め, MIBGの心筋クリアランスが50%から27%に低下する所見が得られた. 症例2はβ遮断薬治療後1か月の経過では自覚症状, 心機能に変化が見られず (EF 11%から13%), MIBG心筋クリアランスは50% (治療前), 46% (1か月後), 50% (3か月後) と経過中変動を示さなかった. β遮断薬投与により心機能の改善が見られた症例では心筋クリアランスが低下したことから, β遮断薬治療により心不全が改善するとともにMIBG心筋シンチ所見も変化している可能性が考えられた. 「I. はじめに」123I-metaiodobenzylguanidine (MIBG) はノルアドレナリンの動態と同様に, 交感神経末端の小胞内に主に集積すると推測され, 心筋へのMIBGの集積やクリアランスは心臓交感神経活動を反映することが報告されている. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Dilated cardiomyopathy, β-blocker, 123I-metaiodobenzylguanidine (MIBG), Myocardial clearance |
|---|
| English |
|---|
| Title | Two Cases of Dilated Cardiomyopathy with the Relationship between the Effect of β-Blocker Therapy and the Changes of Myocardial Clearance of 123I-Metaiodobenzylguanidine |
|---|
| Subtitle | |
|---|
| Authors | Mitsuru MOMOSE*, Hideki KOBAYASHI*, Katsumi SAITO**, Toshinobu HORIE**, Masako MAKI*, Saichi HOSODA**, Kiyoko KUSAKABE* |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Radiology, Tokyo Women's Medical College, **The Heart Institute of Japan, Tokyo Women's Medical College |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 32 |
|---|
| Number | 3 |
|---|
| Page | 301-306 |
|---|
| Year/Month | 1995/3 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] Two cases diagnosed dilated cardiomyopathy received β-blocker therapy, and underwent 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy before and after the treatment. In case 1, symptoms and cardiac function were improved in 1 month and 4 months after the treatment (LVEF increased from 19% to 32% and 40%), and myocardial clearance of MIBG decreased from 50% to 27% and 29%. In case 2, both symptoms and cardiac function were not improved in 1 month and 3 months after the treatment (LVEF was changed from 11% to 10% and 13%), and myocardial clearance was not significantly different between before (50%) and after (1 month : 46%, 3 months : 50%) the treatment. It was indicated that myocardial clearance of MIBG might depend on the extent of the improvement of cardiac function and symptoms, and might reflect the effects of β-blocker therapy. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Dilated cardiomyopathy, β-blocker, 123I-metaiodobenzylguanidine (MIBG), Myocardial clearance |
|---|